Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ
35.45
-0.68 (-1.88%)
Closed
Oct 8, 2026
Day's Range
34.8536.35
52 wk Range
22.9542.81
Financial Statements - INDV - Indivior Pharmaceuticals, Inc.
Revenue
1.23B▲ 4.3%
Net Income
210.00M▲ 6900.0%Net Margin 16.9%
EBITDA
307.00M▲ 9.6%
Free Cash Flow
-94.00M▼ 1980.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.23B | 1.18B | 1.09B | 901M | 791M | 647M |
| Cost of Goods | 246M | 231M | 186M | 159M | 127M | 97M |
| Gross Profit | 993M | 957M | 907M | 742M | 664M | 550M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 265M | 228M | -8M | -91M | 181M | -156M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -3M | - | - | - | - | - |
| Pre Tax Income | 239M | 14M | 1M | -95M | 190M | -173M |
| Income Tax | 29M | 11M | -1M | -42M | -15M | -25M |
| Net Income | 210M | 3M | 2M | -53M | 205M | -148M |
| EPS Basic | 1.68 | -0.36 | 0.01 | -0.38 | 1.4 | -1 |
| EPS Diluted | 1.64 | -0.36 | 0.01 | -0.38 | 1.35 | -1 |
| Basic Shares Outstanding | 125M | 132.30M | 137.30M | 139.01M | 145.65M | 146.57M |
| Diluted Shares Outstanding | 125M | 132.30M | 137.30M | 139.01M | 145.65M | 146.57M |
| Ebit | 284M | 55M | 38M | -66M | 216M | -149M |
| Ebitda | 307M | 280M | 62M | -51M | 206M | -123M |
| Net Income Continuous Operations | 210M | 2M | -4M | -85M | 213M | -156M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
